Access cutting-edge kidney transplant rejection treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.
Access kidney transplant rejection specialists in Seattle at no cost
This study follows strict safety protocols and ethical guidelines
All study-related kidney transplant rejection treatment provided free
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation. After a screening period of up to 6 weeks, eligible participants will be randomized in a 1:1:1 ratio. The study drug will be administered subcutaneously while patients remain on their standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, steroids) during
Sponsor: argenx
Check if you qualify for this kidney transplant rejection clinical trial in Seattle, WA
If you're searching for kidney transplant rejection treatment options in Seattle, WA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced kidney transplant rejection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.